Taken together, our results support the repurposing of BACE1 inhibitors, currently in clinical trials for Alzheimer’s disease, to recover some active IR in the liver of patients with diabetes, thus reducing hepatic insulin resistance. Here, BACE1 is linked to Insulin resistance.